Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irit Allon

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Signal Transduction and Targeted Therapy|February 16, 2026
PKC-eta promotes breast cancer metastasis by regulating the Hippo-YAP signaling pathwayVijayasteltar B Liju, Kamran Waidha, Amitha Muraleedharan, et al.
Neoplasia (New York, N.Y.)|March 21, 2025
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancersDinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, et al.
Cancer Research|February 8, 2023
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck CancerSankar Jagadeeshan, Manu Prasad, Mai Badarni, et al.
Journal for Immunotherapy of Cancer|March 16, 2022
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancerManu Prasad, Jonathan Zorea, Sankar Jagadeeshan, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Signal Transduction and Targeted Therapy|February 16, 2026
PKC-eta promotes breast cancer metastasis by regulating the Hippo-YAP signaling pathwayVijayasteltar B Liju, Kamran Waidha, Amitha Muraleedharan, et al.
Neoplasia (New York, N.Y.)|March 21, 2025
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancersDinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, et al.
Cancer Research|February 8, 2023
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck CancerSankar Jagadeeshan, Manu Prasad, Mai Badarni, et al.
Journal for Immunotherapy of Cancer|March 16, 2022
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancerManu Prasad, Jonathan Zorea, Sankar Jagadeeshan, et al.
Pageof 5